Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) is now available.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that its board of directors will meet on April 24, 2025, to review and approve the company’s first-quarter results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance, potentially impacting its market positioning and stakeholder interests.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, focusing on the production and distribution of heparin products and other pharmaceutical services.
YTD Price Performance: 5.05%
Average Trading Volume: 3,652,923
Technical Sentiment Signal: Sell
Current Market Cap: HK$14.42B
Learn more about 9989 stock on TipRanks’ Stock Analysis page.